Amgen receives FDA approval for Repatha to treat pediatric HeFH patients

Amgen receives FDA approval for Repatha to treat pediatric HeFH patients

Source: 
Pharmaceutical Business Review
snippet: 

The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH).